Trial Profile
Characterization of the Innate Immune Response to Candidate HIV Vaccines, an Ancillary Study to HVTN 205
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs GOVX-B11 (Primary)
- Indications HIV infections
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 12 Feb 2013 New trial record
- 24 Jan 2013 Status changed from active, no longer recruiting to completed, according to the ClinicalTrials.gov record.